Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618196 | 0.90 | MEN1 (0.53) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL21671263 | 0.83 | MEN1 (0.56) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL25002073 | 0.82 | MEN1 (0.54) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19042827 | 0.82 | MEN1 (0.58) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL18268264 | 0.79 | MEN1 (0.52) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL16252543 | 0.79 | KMT2A (0.57) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL22394067 | 0.78 | MEN1 (0.53) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL22855985 | 0.76 | MEN1 (0.50) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19901167 | 0.76 | KMT2A (0.54) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL19339964 | 0.75 | KMT2A (0.51) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130209494-A1 | ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | OXFORD BIOTHERAPEUTICS LTD (GB) | 2013-06-20 | — | — | US | disclosed |
| US-8420084-B2 | Fully human antibodies specific to CADM1 | MEDAREX, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8394922-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | MEDAREX, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120093826-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | OXFORD BIOTHERAPEUTICS LTD (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | MEDAREX, INC. (US) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027274-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | MEN1 333/4885KMT2A 2238/4885CA12 1807/4885 |
| US-20120093826-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | FCGR1A, FCGR2A, FCGR3B | MEN1 1664/4885KMT2A 1990/4885CA12 640/4885 |
| US-20130189256-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | MEN1 333/4885KMT2A 2238/4885CA12 1807/4885 |
| US-20130209494-A1 | ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR | ECI1, DHFR, NQO1 | MEN1 197/4885KMT2A 3620/4885CA12 4148/4885 |
| US-20130156788-A1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | FCGR1A, FCGR2A, FCGR3B | MEN1 1664/4885KMT2A 1990/4885CA12 640/4885 |
| US-20130197259-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | MEN1 333/4885KMT2A 2238/4885CA12 1807/4885 |
| US-20130204033-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | MEN1 333/4885KMT2A 2238/4885CA12 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.